(Q34898980)

5 August 2017

title

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer (English)

1 reference

randomized controlled trial

5 August 2017

main subject

phase III clinical trial

0 references

patient

0 references

1 reference

1 reference

Fred Saad

1 reference

5 August 2017

Michael Carducci

1 reference

5 August 2017

Joel B Nelson

1 reference

5 August 2017

William Love

1 reference

5 August 2017

Joseph L Chin

1 reference

5 August 2017

Claude C Schulman

1 reference

5 August 2017

Darryl J Sleep

1 reference

5 August 2017

Jiang Qian

1 reference

5 August 2017

Joyce Steinberg

1 reference

5 August 2017

Atrasentan Phase 3 Study Group

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2008

1 reference

5 August 2017

1 reference

5 August 2017

volume

113

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

2478-2487

1 reference

5 August 2017

cites work

Cancer statistics, 2007

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Endothelin receptor A blockade enhances taxane effects in prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Global cancer statistics, 2002

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Endothelin receptors as novel targets in tumor therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

The endothelin axis: emerging role in cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Role of endothelin-1 in osteoblastic bone metastases

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Bone metastases: improving the therapeutic index

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3085548

Distinct patterns of endothelin axis expression in primary prostate cancer

26 October 2018

1 reference

12 December 2020

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

1 reference

12 December 2020

Expression of endothelin receptor a associated with prostate cancer progression

1 reference

12 December 2020

A unifying family of group sequential test designs

1 reference

12 December 2020

Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCNCR.23864

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/CNCR.23864

1 reference

5 August 2017

1 reference

5 August 2017

1 reference